PT1002542E - Utilizacao de vip para a preparacao de um medicamento destinado ao tratamento de choque endotoxico em mamiferos - Google Patents

Utilizacao de vip para a preparacao de um medicamento destinado ao tratamento de choque endotoxico em mamiferos

Info

Publication number
PT1002542E
PT1002542E PT99913324T PT99913324T PT1002542E PT 1002542 E PT1002542 E PT 1002542E PT 99913324 T PT99913324 T PT 99913324T PT 99913324 T PT99913324 T PT 99913324T PT 1002542 E PT1002542 E PT 1002542E
Authority
PT
Portugal
Prior art keywords
vip
mammals
treatment
endotoxic shock
medication
Prior art date
Application number
PT99913324T
Other languages
English (en)
Inventor
Gomariz Rosa Perez
Martinez Javier Leceta
Mora Mario Delgado
Mora Carmen Martinez
Original Assignee
Univ Madrid Complutense
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Complutense filed Critical Univ Madrid Complutense
Publication of PT1002542E publication Critical patent/PT1002542E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
PT99913324T 1998-04-17 1999-04-16 Utilizacao de vip para a preparacao de um medicamento destinado ao tratamento de choque endotoxico em mamiferos PT1002542E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009800814A ES2138561B1 (es) 1998-04-17 1998-04-17 Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.

Publications (1)

Publication Number Publication Date
PT1002542E true PT1002542E (pt) 2003-04-30

Family

ID=8303495

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99913324T PT1002542E (pt) 1998-04-17 1999-04-16 Utilizacao de vip para a preparacao de um medicamento destinado ao tratamento de choque endotoxico em mamiferos

Country Status (10)

Country Link
US (1) US6429188B1 (pt)
EP (1) EP1002542B1 (pt)
JP (1) JP2002507224A (pt)
AT (1) ATE228006T1 (pt)
AU (1) AU3148699A (pt)
CA (1) CA2294980A1 (pt)
DE (1) DE69904010T2 (pt)
ES (1) ES2138561B1 (pt)
PT (1) PT1002542E (pt)
WO (1) WO1999053944A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103270E (pt) * 1999-06-04 2003-08-29 Univ Madrid Complutense Tratamento de doencas auto-imunes em mamiferos
WO2003096024A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)
US7547450B2 (en) * 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
NZ537089A (en) * 2003-02-24 2007-07-27 Morinaga Milk Industry Co Ltd Interleukin 6 production inhibitor
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
PT3311828T (pt) 2009-08-14 2021-05-05 Phasebio Pharmaceuticals Inc Péptidos intestinais vasoativos modificados
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides

Also Published As

Publication number Publication date
ES2138561B1 (es) 2000-07-01
ES2138561A1 (es) 2000-01-01
EP1002542B1 (en) 2002-11-20
JP2002507224A (ja) 2002-03-05
EP1002542A1 (en) 2000-05-24
US6429188B1 (en) 2002-08-06
DE69904010D1 (de) 2003-01-02
DE69904010T2 (de) 2003-08-21
ATE228006T1 (de) 2002-12-15
AU3148699A (en) 1999-11-08
CA2294980A1 (en) 1999-10-28
WO1999053944A1 (es) 1999-10-28

Similar Documents

Publication Publication Date Title
PT1002542E (pt) Utilizacao de vip para a preparacao de um medicamento destinado ao tratamento de choque endotoxico em mamiferos
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
DE69733994D1 (de) Sauger zur medikamentenverabreichung
PT2145627E (pt) Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais
EP0651639A4 (en) METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS.
IS2606B (is) Bindill tengdur æxlisdrepþætti
EP0270690A4 (en) MEDICINES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER AND KIDNEY DISEASES.
ZA97986B (en) Treatment of liquors.
ES2152479T3 (es) Uso de preparaciones de inmunoglobulinas para la fabricacion de un medicamento de administracion oral para el tratamiento y la profilaxis de estados de dolor cronico.
CA2218145A1 (en) Method of treating dilated cardiomyopathy
BR9702238A (pt) Uso de um composto composto para uso no tratamento ou prenvenção de uma doença ou patologia envolvendo a produção de citocinas formulação farmacêutica processos de identificaç o de um composto de preparação de um composto e de tratamento ou prevenção de uma doença ou patologia envolvendo uma citocina e composto ou ligando para uso no processo de identificação
NZ226677A (en) Avian vaccine and composition against e.coli
HUP9902415A3 (en) Solid instant-release forms of administration and process for producing the same
ZA929390B (en) The use of D-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects.
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
DE59712344D1 (de) Verwendung von peptidischen Bradykinin-Antagonisten zur Herstellung von Arzneimitteln
NZ332688A (en) Stimulation of host defence mechanisms against tumors using interferon
EP1083927A4 (en) HUMAN "MINOR VAULT" PROTEIN P193
ZA891242B (en) 24r-scymnol,and preparation and use thereof
AU587100B2 (en) Start, hot restart and operating lamp circuit
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
AU8760298A (en) Coup-tfi directed therapies in the treatment of disease
ES2055421T3 (es) Uso de clormetiazol en la fabricacion de un medicamento para la prevencion y/o el tratamiento de neurodegeneracion.
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.